Adjuvant Treatment with Alpha Interferon (IFN) for Patients at High Risk for Relapse after Allogeneic Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

被引：1
|
作者：
Bezerra, Evandro Dantas [1 ]
Radich, Jerald [2 ]
Flowers, Mary E. [2 ]
Chielins, Debbie [3 ]
Higano, Celestia [4 ]
机构：
[1] Univ Washington, Med, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[3] Seattle Canc Care Alliance, Oncol, Seattle, WA USA
[4] Univ Washington, Dept Med, Seattle, WA USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 03期
关键词：
D O I：
10.1016/j.bbmt.2017.12.224
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
326
引用
收藏
页码：S238 / S238
页数：1
相关论文
共 50 条
  • [21] Long-Term Results of Donor Lymphocyte Transfusions for the Treatment of Relapse After Allogeneic Transplantation for Chronic Myelogenous Leukemia - Is There a Role for Immunotherapy in CML?
    Kolb, Hans-Jochem
    Bund, Dagmar
    Schmetzer, Helga
    Schmid, Christoph
    Buhmann, Raymund
    Tischer, Johanna
    Ledderose, Georg
    BLOOD, 2009, 114 (22) : 890 - 890
  • [22] Association of hla phenotype and response to interferon alfa (IFN) in patients with chronic myelogenous leukemia (CML).
    Cortes, J
    Kantarjian, H
    Talpaz, M
    BLOOD, 1995, 86 (10) : 1739 - 1739
  • [23] Early treatment decisions with interferon alpha (IFN-A) therapy in early chronic phase chronic myelogenous leukemia (CP-CML).
    Sacchi, S
    Kantarjian, K
    Smith, T
    OBrien, S
    Pierce, S
    Kornblau, S
    Beran, M
    Keating, M
    Talpaz, M
    BLOOD, 1997, 90 (10) : 2303 - 2303
  • [24] Treatment of chronic myelogenous leukemia (CML) with allogeneic bone marrow transplantation after preparation with BuCy2.
    Copelan, EA
    Biggs, JC
    Szer, J
    Crilley, P
    Atkinson, K
    Avalos, B
    Topolsky, D
    Penza, SL
    Elder, PJ
    Bulova, SL
    Brodsky, I
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 670 - 670
  • [25] Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation
    Sekhri, Arunabh
    Liu, Delong
    Rasu, Muhammad
    Ahmed, Nasir
    Ahmed, Tauseef
    Seiter, Karen
    LEUKEMIA RESEARCH, 2009, 33 (09) : 1291 - 1293
  • [26] Levels of minimal residual disease in chronic myelogenous leukemia (CML) patients in complete cytogenetic remission after interferon-alpha-therapy correlate with risk of relapse.
    Hochhaus, A
    Lin, F
    Reiter, A
    Skladny, H
    Shepherd, PCA
    Sill, H
    Allan, NC
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 579 - 579
  • [27] ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IN PATIENTS WITH CHRONIC MYELOCYTIC-LEUKEMIA (CML)
    EHNINGER, G
    OSTENDORF, P
    HAEN, M
    LINK, H
    DOPFER, R
    NIETHAMMER, D
    HUBENER, K
    BREITLING, G
    SCHNEIDER, W
    WALLER, HD
    BLUT, 1985, 51 (03): : 159 - 159
  • [28] LYMPHOHEMOPOIETIC AND STROMAL CHIMERISM AFTER ALLOGENEIC BMT FOR CHRONIC MYELOGENOUS LEUKEMIA
    SCHMITZ, N
    SCHMIDT, G
    SUTTORP, M
    JOHANNSON, W
    GASSMANN, W
    LOFFLER, H
    EXPERIMENTAL HEMATOLOGY, 1988, 16 (06) : 500 - 500
  • [29] RECURRENCE OF CHRONIC MYELOGENOUS LEUKEMIA IN DONOR CELLS AFTER ALLOGENEIC BMT
    SCHMIDT, G
    SCHMITZ, N
    JOHANNSON, W
    SUTTORP, M
    BARTRAM, C
    GASSMANN, W
    LOFFLER, H
    EXPERIMENTAL HEMATOLOGY, 1988, 16 (06) : 500 - 500
  • [30] BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) - A MULTIINSTITUTIONAL STUDY
    ELFENBEIN, G
    WEINER, R
    WINTON, E
    VOGLER, R
    LAZARUS, H
    STEWART, M
    FLAUM, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 206 - 206
12345